Lithium MOA & levels
Exact mechanism of action is unknown (generally stimulates inhibitory neurotransmission and inhibits excitatory transmission)
reduces excitatory (dopamine and glutamate) but increases inhibitory (GABA) neurotransmission;
.6-1.2
Half life is 24 hours, steady state is achieved about 5 days
Lithium (lab monitoring)
Lithium (side effects)
Nausea (10-20% of patients)
Diarrhea
Polyuria & polydipsia (up to 70% of patients)
Tremor (up to 25% of patients)
Sexual dysfunction
Weight gain
Cognitive impairment
Increased risk of serotonin syndrome with SSRI/SNRIs
Lithium (hydration)
Increased water intake will decrease lithium level, vice versa
Increased salt intake will decrease lithium level, vice versa
Dehydration leads to risk of toxicity as level rises
Valproic Acid (Depakote) MOA & Level
80-125 for acute mania, 50-100 for maintenance
For acute mania, dosing is weight based (15-20mg per kg)
Half life is 24 hours, steady state is achieved about 4-5 days
Valproic Acid (side effects)
Weight gain/insulin resistance Nausea, vomiting Hair loss Sedation Tremor PCOS, amenorrhea, birth defect
Rarely, hepatic failure, thrombocytopenia, pancreatitis
Valproic Acid (blood monitoring)
Prior to starting:
- LFTs, CBC, pregnancy test
During treatment:
Carbamazepine (Tegretol) MOA
may block voltage-sensitive sodium channels and inhibit release of glutamate
Not often prescribed due to how many drug-drug interactions
Lamotrigine (Lamictal) MOA
may reduce the release of excitatory glutamate
Effective for bipolar depression- treatment and prevention, less effective in preventing mania, does not treat active mania or hypomania, does not treat unipolar depression